ZYME - ImmunoPrecise partners with Canada's NRC to develop SARS-CoV-2 therapeutics

Immunoprecise Antibodies (IPATF) has announced a research collaboration with Human Health Therapeutics Research Centre of National Research Council of Canada to develop to develop its neutralizing PolyTope™ antibodies against SARS-CoV-2.For pre-clinical and clinical manufacturing of its lead monoclonal antibodies, the company is also considering acquiring a license for NRC CHO cell-based rapid expression platform.The project is also in partnership with Zymeworks Inc. (ZYME) for the design and development of IPA's lead antibody candidates.The monoclonal antibodies directed against the SARS-CoV-2 virus spike protein were Identified in by the company in summer of 2020.“IPA is pleased to contribute to this Canadian endeavor with the NRC and Zymeworks," stated Jennifer Bath, CEO of ImmunoPrecise, who also added “we believe this partnership between the NRC (HHT, PRCP and IRAP) and Zymeworks to have tremendous potential to generate best-in-class SARS-CoV-2 therapeutics within this expert and motivated team environment in Canada."

For further details see:

ImmunoPrecise partners with Canada’s NRC to develop SARS-CoV-2 therapeutics